<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of the hospitalized child or adolescent with acute severe ulcerative colitis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of the hospitalized child or adolescent with acute severe ulcerative colitis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of the hospitalized child or adolescent with acute severe ulcerative colitis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Athos Bousvaros, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mala Setty, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jess L Kaplan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melvin B Heyman, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H349550314">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis (UC) and Crohn disease (CD). These disorders have distinct pathologic and clinical characteristics  (
         <a class="graphic graphic_table graphicRef74564" href="/z/d/graphic/74564.html" rel="external">
          table 1
         </a>
         ), but their pathogenesis remains poorly understood. (See
         <a class="medical medical_review" href="/z/d/html/4066.html" rel="external">
          "Definitions, epidemiology, and risk factors for inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
         UC disease activity varies substantially among patients, and individual patients may experience variable disease activity over time. Among health care encounters for children with active UC, approximately 5 percent have acute severe colitis [
         <a href="#rid1">
          1
         </a>
         ]. Some of these cases will be the initial manifestation of UC, while others represent exacerbations or "flares" of the chronic disease. The management of these patients is reviewed here. Other aspects of the diagnosis and management of children with UC are discussed in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">
          "Clinical presentation and diagnosis of inflammatory bowel disease in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H349550554">
         <span class="h1">
          DEFINING DISEASE SEVERITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disease severity is typically assessed using the pediatric UC activity index (PUCAI)  (
         <a class="graphic graphic_table graphicRef69607" href="/z/d/graphic/69607.html" rel="external">
          table 2
         </a>
         ) (
         <a class="calc calc_professional" href="/z/d/html/122272.html" rel="external">
          calculator 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. A PUCAI score of 65 to 85 indicates severe disease. Such patients typically have profuse bloody diarrhea, abdominal distention, or tenderness and often have fever, tachycardia, anemia, hypoalbuminemia, or leukocytosis.
        </p>
        <p>
         Endoscopic evaluation provides a more accurate assessment of disease activity and should be used for the initial evaluation, periodically thereafter, and any time that the results would alter a medical decision without significantly increasing risk. On sigmoidoscopy, severe disease can be defined as an endoscopic Mayo score of 3 (spontaneous bleeding, ulceration). Further details on the evaluation of disease severity are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents", section on 'Disease severity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2203972901">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of the pretreatment evaluation for a child with acute severe colitis are to exclude alternative or coexisting conditions, determine severity of disease, and determine what supportive care is needed. The assessment typically includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood tests
         </strong>
         – Perform a complete blood count with differential white blood cell count; erythrocyte sedimentation rate and/or C-reactive protein; serum albumin; and serum electrolytes, blood urea nitrogen, and creatinine. These tests help to confirm the diagnosis and evaluate for complications including anemia, hypoalbuminemia, and dehydration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Blood cultures should be performed for patients with fever, radiographic evidence of toxic megacolon, or other signs suggesting bacteremia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stool tests
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Enteric pathogens – Test stool for
         <em>
          Clostridioides
         </em>
         <em>
          difficile
         </em>
         toxins A and B and for enteric pathogens (
         <em>
          Salmonella
         </em>
         ,
         <em>
          Shigella
         </em>
         ,
         <em>
          Yersinia
         </em>
         ,
         <em>
          Campylobacter
         </em>
         ,
         <em>
          Escherichia
         </em>
         <em>
          coli
         </em>
         [and for
         <em>
          Amoeba
         </em>
         if the history suggests possible exposure]) because these infections may mimic or precipitate a flare [
         <a href="#rid3">
          3
         </a>
         ]. Between 5 and 25 percent of children presenting with a flare of UC have underlying
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         [
         <a href="#rid3">
          3-6
         </a>
         ]. If concomitant
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         is diagnosed in a patient with a UC flare, this pathogen is usually treated, even though the clinician may not be certain whether the
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         is the cause of the flare or if it is bacterial colonization. The clinician must then decide whether the appropriate course of action is to treat the
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         , escalate immunosuppressive therapy for inflammatory bowel disease (IBD), or both [
         <a href="#rid7">
          7,8
         </a>
         ]. Details of this evaluation to exclude other causes of colitis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">
          "Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fecal calprotectin – Measuring fecal calprotectin is optional; the result is not useful for diagnosing acute severe colitis but may be useful to follow as part of clinical monitoring for recovery [
         <a href="#rid3">
          3
         </a>
         ]. Elevated fecal calprotectin (eg, &gt;200 mcg/g) indicates colonic inflammation, which could be due to UC or infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tuberculosis screening
         </strong>
         – Prior to beginning immunosuppressive treatment, patients should be evaluated for tuberculosis risk factors and tested for latent infection using an interferon-gamma release assay, if not already done. (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Infection risk'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         — We suggest a plain radiograph at the time of admission for all patients with acute severe colitis to exclude toxic megacolon [
         <a href="#rid3">
          3
         </a>
         ]. A higher level of suspicion should be used for patients on systemic glucocorticoids because these drugs may mask the symptoms of toxic megacolon. Toxic megacolon occurs in approximately 5 percent of patients with severe UC and may be triggered by hypokalemia or opiate use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Criteria for diagnosing toxic megacolon in children with colitis are acute dilation of the transverse colon (diameter &gt;4 cm in children &lt;10 years old or &gt;5.6 cm in patients ≥10 years, with loss of haustral folds) and systemic symptoms (eg, fever, tachycardia, dehydration, electrolyte disturbance, altered level of consciousness, and hypotension) [
         <a href="#rid3">
          3
         </a>
         ]. Patients with toxic megacolon should be promptly evaluated and followed closely by surgeons. Emergency or urgent colectomy may be indicated, depending on the patient's condition [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Surgery'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1381.html" rel="external">
          "Toxic megacolon"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited colonoscopy
         </strong>
         – A limited colonoscopy (ie, flexible sigmoidoscopy) is appropriate for most patients, both to assess disease severity and to exclude cytomegalovirus (CMV) infection [
         <a href="#rid3">
          3,9
         </a>
         ]. Full colonoscopy usually should be avoided in patients with severe colitis because of risks of perforation. The assessment can be performed either prior to the start of steroid therapy or subsequently, if symptoms do not respond promptly to intravenous (IV) glucocorticoids. Exclusion of CMV is important prior to starting rescue medications such as
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         , or Janus kinase (JAK) inhibitors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CMV infection is diagnosed by immunohistochemistry tests on biopsies from areas with active colitis. Polymerase chain reaction (PCR)-based tests on biopsy specimens are not sufficiently specific to diagnose colonic CMV [
         <a href="#rid3">
          3
         </a>
         ], and serum PCR testing is not sufficiently sensitive. Stool culture for CMV has no role in the evaluation because a positive culture may represent either asymptomatic viral shedding or disease. (See
         <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">
          "Approach to the diagnosis of cytomegalovirus infection", section on 'Gastrointestinal disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies in adults with UC on chronic glucocorticoid treatment suggest that superinfection with CMV is common and is associated with a high rate of steroid resistance (40 to 60 percent) [
         <a href="#rid10">
          10
         </a>
         ]. Case series in adults suggest that treatment with antiviral agents may be effective for patients with UC and CMV superinfection [
         <a href="#rid11">
          11,12
         </a>
         ]. A study in children with refractory severe UC reported that 15 percent had CMV identified using immunohistochemistry tests [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H349553974">
         <span class="h1">
          MEDICAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most children and adolescents with acute severe colitis, management begins with a trial of medical therapy  (
         <a class="graphic graphic_algorithm graphicRef142632" href="/z/d/graphic/142632.html" rel="external">
          algorithm 1
         </a>
         ). Surgery is an important alternative, and clinical outcomes of colectomy are generally very good. However, most patients do not desire surgery (at least at the initial presentation of UC) and medical therapy is often successful in achieving and maintaining remission. In addition, medical stabilization of an acutely ill patient may reduce surgical complications. Patients who have medically unresponsive disease, experience intolerable drug side effects, or are at high risk of developing cancer should be referred for surgery. (See
         <a class="local">
          'Surgery'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H349552899">
         <span class="h2">
          Initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with severe disease (pediatric UC activity index [PUCAI] score 65 to 85) typically have profuse bloody diarrhea, abdominal distention or tenderness, and signs of systemic illness (fever, tachycardia, anemia, hypoalbuminemia, leukocytosis). Such patients require urgent hospitalization for supportive care and medical or surgical interventions [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4272016770">
         <span class="h3">
          Supportive care
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hydration
         </strong>
         – We typically provide intravenous (IV) fluids using isotonic fluids at maintenance rates or slightly above. Patients with acute severe colitis are at risk for dehydration because of limited oral intake and increased fluid losses. Dehydration may also increase the risk of syncope or venous thromboembolism (VTE). (See
         <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">
          "Treatment of hypovolemia (dehydration) in children in resource-abundant settings", section on 'Intravenous rehydration therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nutrition
         </strong>
         – Patients may continue a regular diet if they can tolerate it; bowel rest tends to reduce stool volume but does not affect disease activity [
         <a href="#rid3">
          3
         </a>
         ]. Enteral nutrition also should be stopped if toxic megacolon is suspected. (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who have severe pain when they eat or cannot take in adequate calories may require parenteral nutrition until they improve sufficiently to return to enteral feeding or until they proceed to surgery. (See
         <a class="medical medical_review" href="/z/d/html/15634.html" rel="external">
          "Parenteral nutrition in infants and children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anemia
         </strong>
         <strong>
          and hypoalbuminemia
         </strong>
         – Patients with acute severe colitis occasionally require replacement of blood and/or albumin. Anemia is usually caused by a combination of chronic and acute blood loss. We typically transfuse blood for patients with symptomatic hemodynamic instability (tachycardia or orthostasis) or hemoglobin &lt;9 g/dL; this hemoglobin threshold is somewhat higher than is used for patients with chronic anemia and will help compensate for ongoing blood loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with anemia who are hemodynamically stable and have more subacute bleeding, IV iron replacement is a reasonable alternative. Currently available IV iron formulations have low rates of adverse events; formulations and considerations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15647.html" rel="external">
          "Iron deficiency in infants and children &lt;12 years: Treatment", section on 'Intravenous iron therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain management
         </strong>
         – Abdominal pain in inflammatory bowel disease (IBD) has multiple causes and does not always correlate with intestinal inflammation; thus, management requires an individualized approach. Intermittent abdominal pain is common even among patients in clinical remission, possibly due to visceral hypersensitivity, dysmotility, medication-related effects, and anxiety or depression [
         <a href="#rid14">
          14
         </a>
         ]. Severe or escalating abdominal pain should prompt reevaluation for bowel perforation and toxic megacolon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with active IBD, initial strategies for management of the pain include relaxation techniques, hot packs, or oral
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ]. Severe or escalating abdominal pain, or pain out of proportion to disease severity, may be a symptom of bowel perforation and toxic megacolon and should prompt further evaluation. When first-line steps for pain management are not effective, low-dose
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         (0.05 to 0.1 mg/kg, given infrequently) may be used sparingly and with close monitoring in the inpatient setting [
         <a href="#rid3">
          3
         </a>
         ]. Such patients should be monitored closely by clinicians with experience in managing pediatric colitis because of theoretical concerns that these drugs may increase the risk for toxic megacolon. Of note, a systematic review concluded that opioids are not effective for the management of abdominal pain in children, but this review was based on limited evidence and was not focused on children with IBD [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nonsteroidal antiinflammatory drugs (NSAIDs) should be
         <strong>
          avoided
         </strong>
         as they may exacerbate disease activity [
         <a href="#rid3">
          3
         </a>
         ]. This was suggested by a retrospective study in adults that found that use of NSAIDs was associated with a 20-fold increase in the risk of IBD onset or exacerbation [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of thromboembolism
         </strong>
         – Hospitalized children and adolescents with IBD are at increased risk for VTE. Risk factors include disease activity, history of previous VTE, central venous catheter, older age, parenteral nutrition, and an underlying hypercoagulable condition [
         <a href="#rid17">
          17
         </a>
         ]. Conservative methods of VTE prevention should be used for all hospitalized patients with IBD, including hydration, mobilization, and use of compression stockings or pneumatic devices if appropriate [
         <a href="#rid17">
          17
         </a>
         ]. Selection of patients for thromboprophylaxis (anticoagulation) is discussed separately [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">
          "Clinical manifestations and complications of inflammatory bowel disease in children and adolescents", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H958838338">
         <span class="h3">
          Intravenous glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         After blood and stool cultures have been obtained, patients should be given IV glucocorticoids. Common practice is to use
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         1 to 1.5 mg/kg per day (up to a maximum of 60 mg daily), divided in one or two daily doses [
         <a href="#rid3">
          3,19
         </a>
         ]. There is some evidence that dosing above 1.5 mg/kg per day does not further improve outcomes [
         <a href="#rid20">
          20
         </a>
         ]. Oral 5-aminosalicylate (5-ASA) preparations should be stopped at the time of hospital admission because 5-ASA preparations are usually ineffective in acute severe exacerbations of colitis and are responsible for worsening colitis in approximately 3 percent of patients [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">
          "Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease", section on '5-aminosalicylic acid (5-ASA)'
         </a>
         .)
        </p>
        <p>
         Patients who respond to initial therapy with glucocorticoids subsequently transition to a different therapy for maintenance. (See
         <a class="local">
          'Maintenance therapy'
         </a>
         below.)
        </p>
        <p>
         The evidence supporting the use of IV glucocorticoids in this setting comes from observational studies in which approximately 70 percent of pediatric patients with acute severe UC responded to high-dose glucocorticoids [
         <a href="#rid19">
          19,20
         </a>
         ]. Additional support comes from clinical trials (mostly involving adult patients) and meta-analyses demonstrating that patients treated with glucocorticoids were more likely to achieve remission compared with those in the placebo group or other controls. These data are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults", section on 'Glucocorticoids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">
          "Management of the hospitalized adult patient with severe ulcerative colitis", section on 'Systemic glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3583620449">
         <span class="h3">
          Antibiotics (selected patients)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibiotics are indicated in cases of suspected bacteremia,
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         or other enteric infection, and toxic megacolon and are continued until blood and stool cultures are negative.
        </p>
        <p>
         For children who are not suspected to have these conditions, antibiotics are not routinely recommended, due to lack of evidence for benefit on medium- or long-term outcomes. However, some clinicians utilize oral, multidrug antibiotic regimens empirically and/or for colon salvage therapy in corticosteroid-refractory patients with severe colitis. Support for the latter practice comes from a randomized trial (the PRASCO trial) in which the addition of antibiotics (the combination of
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         /
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         ) to IV glucocorticoids may reduce disease activity after five days but did not alter rates of response rates at hospital discharge or long-term colectomy [
         <a href="#rid21">
          21
         </a>
         ]. Another study suggested that antibiotics may also be helpful in inducing remission when utilized in conjunction with anti-tumor necrosis factor (anti-TNF) agents [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">
          "Management of the hospitalized adult patient with severe ulcerative colitis", section on 'Inpatient management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349553101">
         <span class="h2">
          Subsequent steps for steroid-refractory disease
         </span>
        </p>
        <p class="headingAnchor" id="H2403317086">
         <span class="h3">
          Deciding on medical versus surgical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Steroid-refractory UC is defined as a lack of response after seven days of IV glucocorticoids and is present in approximately 30 to 40 percent of children with acute severe colitis [
         <a href="#rid3">
          3,18
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timeline
         </strong>
         – Our approach to children who are not responding to IV glucocorticoids is as follows  (
         <a class="graphic graphic_algorithm graphicRef142632" href="/z/d/graphic/142632.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Day 3 to 5 – Discuss and reevaluate. If the child has not responded to three to five days of IV glucocorticoids, steroid-refractory disease is likely. These findings should prompt discussion of and preparation for adding a rescue medication (eg,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ). We also suggest educating the family about colectomy as a treatment option. Ideally, this should include consultation with a surgeon with expertise in IBD, if the patient and family are ready to learn more about this option.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In such patients, a flexible sigmoidoscopy is usually indicated to assess disease severity, inform treatment decisions, and exclude cytomegalovirus (CMV) infection if not already done. CMV infection should be excluded before escalating medical therapy or surgery because it is associated with steroid-refractory disease and may respond to antiviral treatment. (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Day 5 to 7 – Change therapy for persistent severe colitis. If the child has severe colitis (PUCAI &gt;65) after five to seven days of IV glucocorticoids, proceed to "rescue" medical therapy (biologics or calcineurin inhibitors) or urgent colectomy, using shared decision-making, as described below.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Day 7 to 10 – Change therapy for partial responders. For children with persistent moderate disease (PUCAI 35 to 64) after 7 to 10 days of IV glucocorticoid therapy, proceed to "rescue" medical therapy or colectomy [
         <a href="#rid3">
          3
         </a>
         ]. This approach is supported by a prospective study in which a PUCAI score &lt;45 on day 3 of IV glucocorticoids was a good predictor of steroid treatment success [
         <a href="#rid19">
          19
         </a>
         ]. Furthermore, a PUCAI score &gt;70 on day 5 of IV glucocorticoids was a strong predictor that steroid treatment would not be successful (specificity and positive predictive value 100 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Shared decision-making
         </strong>
         – For patients with steroid-refractory disease, options include surgical colectomy or a trial of escalating medical therapy  (
         <a class="graphic graphic_algorithm graphicRef142632" href="/z/d/graphic/142632.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Surgery – The possibility of surgery should be presented early in the course of acute severe colitis because it is an important alternative to medical therapy for steroid-refractory disease. Moreover, a substantial number of patients who choose escalating medical therapy will ultimately require surgery [
         <a href="#rid3">
          3,23
         </a>
         ]. The main disadvantage of surgery is that it is an invasive procedure with attendant risks. After restoration of bowel continuity, most patients have moderately increased stool frequency. Long-term risks include inflammation in the pouch (pouchitis) and reduced fertility in females. Nonetheless, clinical outcomes of colectomy are generally very good. For some patients who are very ill or who have a history of difficult-to-treat, medically refractory disease, surgery may be considered instead of medical therapy at this stage. Surgeons with experience in IBD should be consulted early in the hospital course, particularly if there is a poor initial response to IV corticosteroids. (See
         <a class="local">
          'Surgery'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Escalating medical therapy – For patients who are reluctant to undergo colectomy and/or need more time to make the decision about surgery, we offer escalating medical therapy with anti-TNF agents (typically
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ) or calcineurin inhibitors (
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         ), which are sometimes known as "rescue" or "salvage" therapies (see
         <a class="local">
          'Escalating medical therapy ("rescue")'
         </a>
         below). Although these drugs induce remission in approximately 75 percent of children with acute severe colitis, many patients ultimately require colectomy, based on limited data [
         <a href="#rid18">
          18,24,25
         </a>
         ]. The possible benefits of using infliximab, cyclosporine, or tacrolimus must be weighed against the serious risks of these drugs (infection, nephrotoxicity, and neurotoxicity for calcineurin inhibitors, and infection and infusion reactions for infliximab). (See
         <a class="local">
          'Escalating medical therapy ("rescue")'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H703991174">
         <span class="h3">
          Escalating medical therapy ("rescue")
         </span>
         <span class="headingEndMark">
          —
         </span>
         If escalating medical therapy is chosen for children with steroid-refractory disease, the main options are anti-TNF agents and calcineurin inhibitors [
         <a href="#rid3">
          3
         </a>
         ]. Suggested dosing and monitoring are outlined in the table  (
         <a class="graphic graphic_table graphicRef98961" href="/z/d/graphic/98961.html" rel="external">
          table 3
         </a>
         ), and clinical evidence is described below.
        </p>
        <p>
         The majority of centers in the United States utilize
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         as first-line rescue therapy in acute severe colitis due to ease of use (less frequent infusions and less monitoring required compared with a calcineurin inhibitor). However, observational evidence suggests that calcineurin inhibitors have comparable efficacy. In an observational study from a single center, patients treated with infliximab or a calcineurin inhibitor for six months had similar rates of colectomy (23 versus 27 percent, respectively) and similar declines in clinical measures of disease activity [
         <a href="#rid26">
          26
         </a>
         ]. There is extensive experience with calcineurin inhibitors in both pediatric and adult IBD centers.
        </p>
        <p>
         Regardless of which of these therapies is chosen, efforts should be made to wean glucocorticoids to reduce the risk of glucocorticoid toxicity or immunosuppression from multiple medications.
        </p>
        <p class="headingAnchor" id="H349555092">
         <span class="h4">
          Anti-tumor necrosis factor agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infliximab
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          Infliximab
         </a>
         is the most commonly utilized option for patients with steroid-refractory disease [
         <a href="#rid3">
          3
         </a>
         ]. This drug is a chimeric monoclonal antibody against TNF-alpha. It is effective in fistulizing, perianal, and steroid-refractory Crohn disease (CD), but its use in pediatric UC is less defined [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Standard induction dosing for
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         is 5 mg/kg, given at weeks 0, 2, and 6. However, because clearance of infliximab is accelerated in the setting of acute severe colitis, more intensive dosing may be needed. For these patients, most centers initiate treatment with higher dosing (10 mg/kg) and/or shorter dosing intervals (eg, weeks 0, 1, and 4 or even more frequently) [
         <a href="#rid3">
          3
         </a>
         ]. In one retrospective study, intensified infliximab induction (defined as mean induction dose ≥7 mg/kg or interval ≤5 weeks between doses 1 and 3) was associated with increased remission and lower risk for colectomy in children with steroid-refractory UC but not steroid-dependent UC [
         <a href="#rid28">
          28
         </a>
         ]. If intensive dosing is used initially and the patient responds, the dose may be gradually lowered and adjusted toward standard dosing, ideally guided by therapeutic drug monitoring. One retrospective study and meta-analysis in adults suggests that higher doses of infliximab may reduce initial colectomy rates, but long-term outcomes are similar whether standard 5 mg/kg or 10 mg/kg doses are used [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents", section on 'Infliximab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among children treated with
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         for steroid-refractory UC, approximately 75 percent have a short-term response to infliximab, but only 30 to 65 percent have sustained response one year later, based on several observational studies [
         <a href="#rid18">
          18,24,30
         </a>
         ]. One of these studies reported that "stepping up" therapy, by either increasing the dose to 10 mg/kg or decreasing the time between infusions, was associated with higher response rates in a subset of nonresponders [
         <a href="#rid30">
          30
         </a>
         ]. Infliximab also appears to modestly reduce the likelihood of colectomy and overall use of glucocorticoids. In a retrospective multicenter study, 45 children treated with infliximab for UC had a cumulative risk of colectomy of 21 percent within one year and 26 percent within two years; the likelihood of requiring concomitant glucocorticoid treatment was 32 percent within one year and 48 percent within two years [
         <a href="#rid31">
          31
         </a>
         ]. The efficacy and safety of infliximab and other anti-TNF agents for UC, including large randomized trials in adults, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4054.html" rel="external">
          "Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adalimumab
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          Adalimumab
         </a>
         is approved by the US Food and Drug Administration (FDA) for use in children with moderate to severe pediatric UC, but its role in acute severe colitis is not clear, because of limited clinical evidence in children. Therefore, we generally use
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         rather than adalimumab for children hospitalized with acute severe UC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The FDA approval was based on a phase 3 study that showed meaningful rates of response/remission and mucosal healing in 62 pediatric patients compared with external adult controls (a meta-analysis of the placebo arms in several trials in adults with UC). Patients treated with high-dose
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         for induction had higher rates of remission at week 8 compared with those on standard dosing [
         <a href="#rid32">
          32
         </a>
         ]. Among those who did respond by week 8, the proportion who were in remission at one year was 45 percent (14 of 31 patients) for those treated with weekly maintenance adalimumab (0.6 mg/kg, maximum dose 40 mg), 29 percent (9 of 31 patients) for those dosed every other week, and 20 percent in the external placebo adult comparison group. Based on these findings, adalimumab is dosed more frequently for children with UC than for those with CD. (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents", section on 'Adalimumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination therapy
         </strong>
         – Combination therapy with an anti-TNF agent and an immunomodulator (
         <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         ) in children with UC is controversial. One randomized trial in adults with steroid-refractory colitis reported improved remission rates for combination treatment with azathioprine and
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         compared with either agent alone [
         <a href="#rid33">
          33
         </a>
         ]. In addition, combination therapy has been shown to decrease immunogenicity of infliximab and increase infliximab trough levels in patients with IBD. However, there is a lack of specific evidence to support this practice in children with severe and/or refractory UC. Thus, combination therapy can be entertained but only after careful discussion of the benefit:risk ratio (increased efficacy versus potential increased risk of infection and lymphoma) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The potential benefits and risks of combination therapy are extrapolated from data in adults with UC [
         <a href="#rid33">
          33
         </a>
         ] and children with CD, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Anti-TNF monotherapy versus combination therapy with an immunomodulator'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2911411314">
         <span class="h4">
          Calcineurin inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Calcineurin inhibitors (
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         ) are reasonable alternatives to
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         for patients with refractory disease [
         <a href="#rid3">
          3
         </a>
         ]. These are not maintenance agents. Patients who respond to treatment should be transitioned to a maintenance drug (typically a thiopurine or
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         ), ideally within approximately four to six months or proceed to colectomy. (See
         <a class="local">
          'Maintenance therapy'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclosporine
         </strong>
         – IV
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         (2 to 4 mg/kg per day) has been used at some centers as an alternative to colectomy because it can achieve high rates of short-term clinical remission in adult patients with steroid-refractory colitis, although the majority of these patients ultimately require colectomy. Oral microemulsion (or "modified") cyclosporine also may be effective [
         <a href="#rid34">
          34
         </a>
         ]. The conversion from IV to oral microemulsion is approximately 1:3 for the total daily dose (divided in two doses for the oral form), but drug levels should be monitored and the dose adjusted further as needed. Only a few small trials have addressed the use of cyclosporine in children with UC, with outcomes similar to those seen in adults [
         <a href="#rid3">
          3
         </a>
         ]. A systematic review of eight retrospective pediatric case series reported a pooled short-term response of 81 percent, but the majority of patients (60 percent) went on to colectomy in the long term [
         <a href="#rid18">
          18
         </a>
         ]. The use of this drug in adults with UC is described separately. There are no pediatric studies directly comparing the efficacy of cyclosporine with
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         in severe UC. Adult studies show comparable short- and long-term outcomes for these therapies [
         <a href="#rid35">
          35,36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">
          "Management of the hospitalized adult patient with severe ulcerative colitis", section on 'Cyclosporine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tacrolimus
         </strong>
         – Small observational studies in children suggest that oral
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         (0.2 mg/kg per day in two divided doses) may have comparable efficacy with IV
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         in treating fulminant UC or Crohn colitis [
         <a href="#rid26">
          26,37-39
         </a>
         ]. An observational study reported short-term clinical improvement in 43 of 46 children treated with oral tacrolimus (93 percent), with a marked reduction in PUCAI score [
         <a href="#rid25">
          25
         </a>
         ]. However, approximately 50 percent of children treated with tacrolimus will still require colectomy within two years.
        </p>
        <p>
        </p>
        <p>
         If calcineurin inhibitors (
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         ) are used, we suggest prophylaxis against
         <em>
          Pneumocystis
         </em>
         <em>
          jirovecii
         </em>
         pneumonia [
         <a href="#rid3">
          3,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H313926608">
         <span class="h3">
          Nonresponders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited evidence is available to guide treatment decisions for patients who do not respond to the initial attempt at medical rescue therapy with
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or a calcineurin inhibitor. The risks and benefits of changing to a different immunosuppressant (sequential medical rescue therapy) must be carefully discussed with the patient and family. Use of sequential medical "rescue" therapy is controversial [
         <a href="#rid3">
          3
         </a>
         ]. For most patients in this category, we suggest surgery, as discussed below  (
         <a class="graphic graphic_algorithm graphicRef142632" href="/z/d/graphic/142632.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Surgery'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decision-making
         </strong>
         – Our practice is:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We discuss the option of surgery versus medical therapy again with the patient and family. We review the same considerations that were discussed prior to the initial attempt at medical rescue therapy. We explain that we have limited information about the outcomes of sequential medical therapies, but the likelihood of response is probably lower and the risk of serious infection is higher compared with the initial attempt with
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or a calcineurin inhibitor. (See
         <a class="local">
          'Deciding on medical versus surgical therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most patients who do not respond to the initial attempt at medical rescue therapy (
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or calcineurin inhibitor), we suggest surgery. A surgical consultation is obtained, if not already done. (See
         <a class="local">
          'Surgery'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         However, some patients/caregivers may reasonably choose a second attempt at medical rescue therapy over surgical intervention. For these patients, our approach is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those who did not respond to
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         as the initial therapy, options include a calcineurin inhibitor (as a bridging therapy),
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those who did not respond to a calcineurin inhibitor as the initial therapy, options include
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Sequential use of immunosuppressive agents may increase the risk of infection, but overall risks are generally acceptable, based primarily on indirect evidence from adults with IBD or children with autoimmune diseases, as well as limited but increasing experience with
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         in adults and children, outlined below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second-line rescue agents
         </strong>
         – The main options for alternate medical therapy are Janus kinase (JAK) inhibitors (
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         ). These drugs are approved for use in adults with UC who have not responded to other biologic therapies, but data are limited on their use in children or for acute severe colitis in any age group. In one case series, four of six adults with acute severe colitis who lost their response to
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         achieved corticosteroid-free clinical remission by week 8 of upadacitinib treatment [
         <a href="#rid41">
          41
         </a>
         ]. Similarly, small case series in hospitalized children with refractory UC of varying severity suggest that tofacitinib may be beneficial [
         <a href="#rid42">
          42,43
         </a>
         ]. The experience with these and other agents in adults is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults", section on 'Janus kinase (JAK) inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Safety concerns with JAK kinase inhibitors include infection, hyperlipidemia, thrombosis, and cardiac events. Relevant safety information comes from other populations treated with
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         , including children with juvenile idiopathic arthritis. (See
         <a class="medical medical_review" href="/z/d/html/6428.html" rel="external">
          "Polyarticular juvenile idiopathic arthritis: Treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These drugs are not approved by the FDA for children with UC, but they may be appropriate for selected patients based on individual characteristics and if recommended and managed by an expert clinician, as an "off-label" use [
         <a href="#rid44">
          44
         </a>
         ]. A small study in children with steroid-refractory UC suggests that
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         may reduce the likelihood of colectomy [
         <a href="#rid42">
          42
         </a>
         ]. The limited available data on the use of tofacitinib,
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="126474" href="/z/d/drug information/126474.html" rel="external">
          ustekinumab
         </a>
         in children with nonsevere UC are summarized separately. (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents", section on 'Other options'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Experimental interventions include combination oral antibiotics [
         <a href="#rid45">
          45
         </a>
         ], leukocytapheresis, or rapamycin [
         <a href="#rid46">
          46
         </a>
         ], but these strategies are only supported by small retrospective studies and cannot be recommended at this time.
        </p>
        <p class="headingAnchor" id="H1473183857">
         <span class="h3">
          Medical necessity of off-label use of medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of these second- or third-line agents and/or escalation
         <strong>
         </strong>
         of doses beyond those approved by the FDA may be appropriate and medically necessary for selected children with UC, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents", section on 'Medical necessity of off-label use of medications in pediatrics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1380043557">
         <span class="h2">
          Maintenance therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute severe colitis generally require long-term maintenance with either an immunomodulator and/or anti-TNF agent. The choice of maintenance therapy for severe or refractory colitis depends on which therapy was successfully used for induction:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoid responders
         </strong>
         – Options for maintenance therapy include
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         , thiopurine, or other immunomodulator. The glucocorticoids can be gradually withdrawn by transitioning to oral glucocorticoids, followed by a gradual tapering of the dose. If an immunomodulator is used,
         <a class="drug drug_pediatric" data-topicid="12584" href="/z/d/drug information/12584.html" rel="external">
          mesalamine
         </a>
         or other 5-ASA can be used as an adjunct therapy. (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents", section on 'Maintenance of remission'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-TNF responders
         </strong>
         – If
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         was successful for induction, continue this agent for maintenance therapy and gradually taper the glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcineurin inhibitor responders
         </strong>
         – If a calcineurin inhibitor (
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         ) was used for induction, transition the therapy to
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         (if not previously failed),
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         , thiopurine,
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         . While one guideline suggests weaning patients from calcineurin inhibitors within four months [
         <a href="#rid3">
          3
         </a>
         ], clinicians may reasonably choose to continue treatment beyond this timeframe in special circumstances, keeping in mind the risks of prolonged therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tofacitinib
         </strong>
         <strong>
          or
         </strong>
         <strong>
          upadacitinib
         </strong>
         <strong>
          responders
         </strong>
         – If
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         was used for induction, options include continuing it for maintenance therapy or transitioning to
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         (which may have a better safety profile). (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents", section on 'Other options'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          Vedolizumab
         </a>
         is also occasionally used for patients who stop responding to anti-TNF therapies. It tends to have a slower onset of action compared with other biologic agents but an improved safety profile. Most evidence is extrapolated from studies in adults and a few studies in children with moderate UC. (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents", section on 'Second-line options'
         </a>
         .)
        </p>
        <p>
         Patients with severe colitis who improve sufficiently to be discharged from the hospital remain at high risk of relapse or developing complications of their IBD or of immunosuppression. Therefore, these patients require close follow-up, with monitoring of history, examination, laboratory studies, and therapeutic drug monitoring as necessary. We typically reevaluate these patients in clinic one to two weeks after hospital discharge. Even patients who respond well to medication may not achieve a full clinical remission until 8 to 16 weeks after the initiation of their maintenance therapy.
        </p>
        <p class="headingAnchor" id="H349554228">
         <span class="h1">
          SURGERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         When managed with a modern protocol of medical therapies, approximately 5 to 10 percent of children with UC undergo colectomy within one year of diagnosis and approximately 15 percent within three years [
         <a href="#rid23">
          23,47-49
         </a>
         ]. Outcomes are only partially predicted by disease severity at baseline. (See
         <a class="medical medical_review" href="/z/d/html/5871.html" rel="external">
          "Management of mild to moderate ulcerative colitis in children and adolescents", section on 'Prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349554249">
         <span class="h2">
          Candidates
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Emergency colectomy is required for patients with acute severe colitis and uncontrolled hemorrhage or patients with complications such as toxic megacolon or bowel perforation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition, we suggest colectomy for patients who do not respond to aggressive medical management within two weeks or after failure of medical rescue therapy, such as
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or a calcineurin inhibitor  (
         <a class="graphic graphic_algorithm graphicRef142632" href="/z/d/graphic/142632.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. However, some nonresponders may reasonably choose a second attempt at medical rescue therapy over surgical intervention, as discussed above. (See
         <a class="local">
          'Nonresponders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Elective colectomy also has a role in the chronic management of UC (eg, in patients who are unresponsive to or cannot be weaned from glucocorticoids, who experience unwanted side effects [eg, growth failure from steroids], or who have surveillance biopsies that suggest a risk for developing cancer) [
         <a href="#rid3">
          3,50
         </a>
         ]. Some patients may choose to undergo colectomy earlier in the disease course. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1375.html" rel="external">
          "Surgical management of ulcerative colitis"
         </a>
         .)
        </p>
        <p>
         A small proportion of patients with what appears to be UC will ultimately be diagnosed with Crohn disease (CD), in which case, surgery will not be curative. Even a thorough preoperative evaluation (including review of small bowel imaging and endoscopic, histologic, and serologic data) cannot exclude this possibility. It is likely that a patient with diffuse continuous colitis, no granulomas on biopsy, and no macroscopic small bowel involvement will have UC. Nonetheless, CD may still be diagnosed in 5 to 25 percent of cases [
         <a href="#rid51">
          51,52
         </a>
         ]. Some of these patients who are ultimately diagnosed with CD may need a permanent ileostomy. Patients should be made aware of this possibility.
        </p>
        <p>
         The presence of anti-
         <em>
          Saccharomyces
         </em>
         <em>
          cerevisiae
         </em>
         antibodies (ASCA) is somewhat predictive of which patients with an initial diagnosis of UC or indeterminate colitis may develop evidence of CD after colectomy. In one series, the positive predictive value of ASCA immunoglobulin A (IgA) antibodies was 0.17 and the negative predictive value was 0.94; the positive predictive values are less than a family history of CD [
         <a href="#rid51">
          51
         </a>
         ]. Because of these limited predictive values, these tests should not be used as an important factor in making decisions about colectomy. (See
         <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">
          "Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Differentiation between Crohn disease and ulcerative colitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">
          "Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Antibody testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349554331">
         <span class="h2">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most commonly performed procedure is colectomy and rectal mucosectomy with an endorectal ileoanal pull-through, creation of a distal ileal reservoir, and ileorectal anastomosis (called ileal pouch anal anastomosis [IPAA]). In the urgent surgical setting, a subtotal colectomy, terminal ileostomy, and blind rectal stump are created. After the patient recovers, the rectal mucosectomy and ileoanal pull-through with anastomosis procedure is performed.
        </p>
        <p>
         Addressing medical and psychologic needs prior to surgery is important for the patient and to improve outcomes. Nutritional correction, treatment of infections, and psychological support are crucial. (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Psychological screening and support'
         </a>
         .)
        </p>
        <p>
         Additional details on the pre- and postoperative surgical management of UC are provided in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/1375.html" rel="external">
          "Surgical management of ulcerative colitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349554349">
         <span class="h2">
          Perioperative management of immunosuppressive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most immunosuppressive drugs can be discontinued just before surgery, with the exception of glucocorticoids, which must be tapered after surgery. If possible, efforts should be made to limit corticosteroid exposure before elective or semi-elective colectomy to optimize healing of wounds and intestinal anastomoses.
        </p>
        <p>
         Exposure to immunosuppressive drugs in the preoperative period probably does not have adverse effects on outcomes after surgery, although there is some uncertainty on this point [
         <a href="#rid53">
          53
         </a>
         ]. In one study, preoperative exposure to thiopurines or calcineurin inhibitors within 30 days, or
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         within 90 days, did not significantly affect postoperative outcomes [
         <a href="#rid54">
          54,55
         </a>
         ]. In another study, the use of
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         prior to colectomy reduced disease severity and was not associated with complications [
         <a href="#rid56">
          56
         </a>
         ]. In contrast, whether
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         increases the risk of perioperative complications is controversial. Some studies suggest an increase in peristomal complications, but other meta-analyses have failed to confirm this finding [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1375.html" rel="external">
          "Surgical management of ulcerative colitis", section on 'Routine preoperative care'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349554407">
         <span class="h2">
          Outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Functional outcomes of IPAA for UC are generally good. Patients who undergo this surgery generally have four to eight bowel movements per day, but continence usually can be achieved [
         <a href="#rid58">
          58,59
         </a>
         ]. In one series, 89 percent of patients were continent two years after undergoing IPAA with creation of a J-pouch reservoir [
         <a href="#rid60">
          60
         </a>
         ]. Studies with long-term follow-up describe ongoing improvement in quality of life even many years after surgery, with some continence problems in 10 to 20 percent of patients [
         <a href="#rid59">
          59,61-63
         </a>
         ]. Other complications include reduced fertility in females undergoing the IPAA procedure, and risks for sexual dysfunction in both males and females [
         <a href="#rid53">
          53
         </a>
         ]. These and other surgical considerations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1375.html" rel="external">
          "Surgical management of ulcerative colitis"
         </a>
         .)
        </p>
        <p>
         The major complication occurring after ileoanal pull-through with pouch formation is inflammation of the pouch ("pouchitis"), which occurs in 10 to 30 percent of patients [
         <a href="#rid59">
          59,60
         </a>
         ]. Clinical symptoms of pouchitis include diarrhea, rectal bleeding, abdominal cramping, and malaise. Broad-spectrum antibiotics (
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         ) or glucocorticoid enemas usually are effective therapy; in some patients, systemic steroids are required. Chronic pouchitis eventually develops in approximately 10 percent of patients [
         <a href="#rid63">
          63
         </a>
         ]. Maintenance therapy may include oral bacteriotherapy (probiotics). A diagnosis of CD should be considered in patients in whom pouchitis is chronic and refractory to treatment. (See
         <a class="medical medical_review" href="/z/d/html/4073.html" rel="external">
          "Pouchitis: Epidemiology, pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93857.html" rel="external">
          "Management of acute and chronic pouchitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H924997458">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113229.html" rel="external">
          "Society guideline links: Inflammatory bowel disease in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H568109883">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86458.html" rel="external">
          "Patient education: Ulcerative colitis in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/1991.html" rel="external">
          "Patient education: Ulcerative colitis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H349554729">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease severity
         </strong>
         – Acute severe ulcerative colitis (UC) typically presents with profuse bloody diarrhea, abdominal distention, or tenderness, often with fever, tachycardia, anemia, hypoalbuminemia, or leukocytosis. Severe disease is usually defined by a score of &gt;65 on the pediatric UC activity index (PUCAI)  (
         <a class="graphic graphic_table graphicRef69607" href="/z/d/graphic/69607.html" rel="external">
          table 2
         </a>
         ) (
         <a class="calc calc_professional" href="/z/d/html/122272.html" rel="external">
          calculator 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Defining disease severity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – Children with acute severe colitis require urgent evaluation to diagnose alternative or coexisting conditions and to determine the severity and extent of disease. The evaluation includes stool tests to exclude enteric infections that may mimic or precipitate a flare (especially
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         ), abdominal radiograph to evaluate for toxic megacolon, and usually a flexible sigmoidoscopy or colonoscopy to assess disease severity and test for cytomegalovirus (CMV) colitis using colonic biopsies. (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Supportive care
         </strong>
         – Patients with severe disease should be urgently admitted to a hospital. Supportive care includes hydration, nutrition, pain management, and, in some cases, blood transfusion or albumin replacement. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Glucocorticoids
         </strong>
         – For patients with acute severe colitis, we recommend initiating treatment with high-dose intravenous (IV) glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Intravenous glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibiotics
         </strong>
         – Patients with suspected bacteremia,
         <em>
          C
         </em>
         .
         <em>
          difficile
         </em>
         infection or toxic megacolon require broad-spectrum antibiotics, which are continued until blood and stool cultures are negative. Some clinicians utilize broad-spectrum antibiotics more liberally, as part of induction therapy. (See
         <a class="local">
          'Antibiotics (selected patients)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Steroid-refractory disease
         </strong>
         – Patients who do not have a clinically meaningful response to a seven-day course of IV glucocorticoids have steroid-refractory disease. Concomitant enteric infections should be carefully excluded if not already done, including stool cultures,
         <em>
          C. difficile
         </em>
         toxin, and assessment for CMV infection via sigmoidoscopy. (See
         <a class="local">
          'Subsequent steps for steroid-refractory disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment options include surgical colectomy or a trial of escalating medical therapy  (
         <a class="graphic graphic_algorithm graphicRef142632" href="/z/d/graphic/142632.html" rel="external">
          algorithm 1
         </a>
         ). These options should be discussed with the patient and caregivers early in the disease course (once it is apparent that the child has not responded adequately to IV glucocorticoids). The choice between surgery versus escalating medical therapy is individualized, depending on the child's condition and history of prior flares, as well as the patient's and family's values and preferences. Key points during shared decision-making with the family are (see
         <a class="local">
          'Deciding on medical versus surgical therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The advantage of surgery is that it removes the diseased colon. The main disadvantage is that it is an invasive procedure with attendant risks (including both procedure-related risks and long-term risks, which include pouchitis and possible reduced fertility in females). However, clinical outcomes of colectomy are generally very good. (See
         <a class="local">
          'Surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The main options for escalating medical therapy are a trial of an anti-tumor necrosis factor (anti-TNF) agent therapy (typically
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ) or a calcineurin inhibitor (
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         )  (
         <a class="graphic graphic_table graphicRef98961" href="/z/d/graphic/98961.html" rel="external">
          table 3
         </a>
         ). Most children achieve short-term remission with these treatments, but less than one-third achieve long-term glucocorticoid-free remission. The main advantage of escalating medical therapy is that it may avoid the need for surgery. However, many patients ultimately require colectomy. In addition, the potential benefits of these medications must be weighed against the risks of these drugs (infection and infusion reactions for infliximab and infection, nephrotoxicity, and neurotoxicity for calcineurin inhibitors). (See
         <a class="local">
          'Escalating medical therapy ("rescue")'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Escalating medical therapy
         </strong>
         – For most patients with steroid-refractory disease who opt for escalated medical therapy, we suggest
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         rather than other agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A calcineurin inhibitor (
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         ) is a reasonable alternative. Our preference for infliximab is based on its ease of use (less frequent infusions, less monitoring). Observational data suggest that infliximab and calcineurin inhibitors have comparable efficacy. (See
         <a class="local">
          'Escalating medical therapy ("rescue")'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintenance medical therapy
         </strong>
         – Patients with acute severe colitis generally require long-term maintenance with either an immunomodulator and/or anti-TNF agent or other biologic agent (eg,
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         ). The choice of maintenance therapy for severe or refractory colitis depends on which therapy was successfully used for induction. (See
         <a class="local">
          'Maintenance therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgery
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Emergency colectomy is required for patients with acute severe colitis and uncontrolled hemorrhage or complications such as toxic megacolon or bowel perforation. (See
         <a class="local">
          'Candidates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In addition, we suggest colectomy for patients with acute severe UC and no improvement within two weeks of aggressive medical management
         <strong>
          or
         </strong>
         after failure of a first attempt at medical rescue therapy (eg,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or a calcineurin inhibitor) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, some nonresponders may reasonably choose a second attempt at medical rescue therapy (eg with
         <a class="drug drug_pediatric" data-topicid="129936" href="/z/d/drug information/129936.html" rel="external">
          tofacitinib
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="134956" href="/z/d/drug information/134956.html" rel="external">
          upadacitinib
         </a>
         ) rather than surgical intervention. (See
         <a class="local">
          'Candidates'
         </a>
         above and
         <a class="local">
          'Nonresponders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Potential complications of colectomy include incontinence, pouchitis, and reduction in fertility among females. (See
         <a class="local">
          'Outcomes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         <strong>
          ACKNOWLEDGMENT
         </strong>
         — The UpToDate editorial staff acknowledges George H Russell, MD, MS, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Dotson JL, Crandall WV, Zhang P, et al. Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice. J Pediatr Gastroenterol Nutr 2015; 60:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinelli M, Strisciuglio C, Veres G, et al. Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study. Inflamm Bowel Dis 2014; 20:2219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandberg KC, Davis MM, Gebremariam A, Adler J. Disproportionate rise in Clostridium difficile-associated hospitalizations among US youth with inflammatory bowel disease, 1997-2011. J Pediatr Gastroenterol Nutr 2015; 60:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidovics ZH, Michail S, Nicholson MR, et al. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2019; 68:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lukin DJ, Lawlor G, Hudesman DP, et al. Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile. Inflamm Bowel Dis 2019; 25:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen S, Martinez-Vinson C, Aloi M, et al. Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis-A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Pediatr Infect Dis J 2018; 37:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayre K, Warren BF, Jeffery K, Travis SP. The role of CMV in steroid-resistant ulcerative colitis: A systematic review. J Crohns Colitis 2009; 3:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 2004; 28:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones A, McCurdy JD, Loftus EV Jr, et al. Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. Clin Gastroenterol Hepatol 2015; 13:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Temtem T, Whitworth J, Zhang J, Bagga B. Cytomegalovirus in pediatric inflammatory bowel disease patients with acute severe colitis. Clin Res Hepatol Gastroenterol 2021; 45:101625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinath A, Young E, Szigethy E. Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside. Inflamm Bowel Dis 2014; 20:2433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poonai N, Paskar D, Konrad SL, et al. Opioid analgesia for acute abdominal pain in children: A systematic review and meta-analysis. Acad Emerg Med 2014; 21:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000; 95:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nylund CM, Goudie A, Garza JM, et al. Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011; 17:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010; 138:2282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choshen S, Finnamore H, Auth MK, et al. Corticosteroid Dosing in Pediatric Acute Severe Ulcerative Colitis: A Propensity Score Analysis. J Pediatr Gastroenterol Nutr 2016; 63:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Bishai J, Reshef L, et al. Antibiotic Cocktail for Pediatric Acute Severe Colitis and the Microbiome: The PRASCO Randomized Controlled Trial. Inflamm Bowel Dis 2020; 26:1733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breton J, Kastl A, Hoffmann N, et al. Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2019; 25:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ihekweazu FD, Fofanova T, Palacios R, et al. Progression to colectomy in the era of biologics: A single center experience with pediatric ulcerative colitis. J Pediatr Surg 2020; 55:1815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010; 105:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 2011; 17:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmerman LA, Spaan J, Weinbren N, et al. Efficacy and Safety of Tacrolimus or Infliximab Therapy in Children and Young Adults With Acute Severe Colitis. J Pediatr Gastroenterol Nutr 2023; 77:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Church PC, Ho S, Sharma A, et al. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis. J Crohns Colitis 2019; 13:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nalagatla N, Falloon K, Tran G, et al. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. Clin Gastroenterol Hepatol 2019; 17:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dan-Nielsen S, Wewer V, Paerregaard A, et al. Does infliximab prevent colectomy in acute and chronic active ulcerative colitis? J Pediatr Gastroenterol Nutr 2014; 58:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Croft NM, Faubion WA Jr, Kugathasan S, et al. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Lancet Gastroenterol Hepatol 2021; 6:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001; 36:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziring DA, Wu SS, Mow WS, et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007; 45:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navas-López VM, Blasco Alonso J, Serrano Nieto MJ, et al. Oral tacrolimus for pediatric steroid-resistant ulcerative colitis. J Crohns Colitis 2014; 8:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okafor PN, Nunes DP, Farraye FA. Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered? Inflamm Bowel Dis 2013; 19:1764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilmore R, Tan L, Fernandes R, et al. Upadacitinib Salvage Therapy for Infliximab experienced patients with Acute Severe Ulcerative Colitis. J Crohns Colitis 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Constant BD, Baldassano R, Kirsch J, et al. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2022; 75:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore H, Dubes L, Fusillo S, et al. Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2021; 73:e57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frattarelli DA, Galinkin JL, Green TP, et al. Off-label use of drugs in children. Pediatrics 2014; 133:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Levine A, Kolho KL, et al. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis 2014; 8:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mutalib M, Borrelli O, Blackstock S, et al. The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children. J Crohns Colitis 2014; 8:1730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams JS, Davis Thomas S, Gotman N, et al. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet 2019; 393:1708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams JS, Brimacombe M, Haberman Y, et al. Clinical and Host Biological Factors Predict Colectomy Risk in Children Newly Diagnosed With Ulcerative Colitis. Inflamm Bowel Dis 2022; 28:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009; 104:2080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melmed GY, Fleshner PR, Bardakcioglu O, et al. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2008; 51:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarchin L, Spencer EA, Khaitov S, et al. De Novo Crohn's Disease of the Pouch in Children Undergoing Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2019; 69:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rentea RM, Renaud E, Ricca R, et al. Surgical Management of Ulcerative Colitis in Children and Adolescents: A Systematic Review from the APSA Outcomes and Evidence-Based Practice Committee. J Pediatr Surg 2023; 58:1861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaufler C, Lerer T, Campbell B, et al. Preoperative immunosuppression is not associated with increased postoperative complications following colectomy in children with colitis. J Pediatr Gastroenterol Nutr 2012; 55:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang Z, Wu Q, Wang F, et al. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther 2012; 36:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gray FL, Turner CG, Zurakowski D, et al. Predictive value of the Pediatric Ulcerative Colitis Activity Index in the surgical management of ulcerative colitis. J Pediatr Surg 2013; 48:1540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lightner AL, Mathis KL, Tse CS, et al. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. Inflamm Bowel Dis 2018; 24:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pakarinen MP, Natunen J, Ashorn M, et al. Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis. Pediatrics 2009; 123:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lightner AL, Alsughayer A, Wang Z, et al. Short- and Long-term Outcomes After Ileal Pouch Anal Anastomosis in Pediatric Patients: A Systematic Review. Inflamm Bowel Dis 2019; 25:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koivusalo A, Pakarinen MP, Rintala RJ. Surgical complications in relation to functional outcomes after ileoanal anastomosis in pediatric patients with ulcerative colitis. J Pediatr Surg 2007; 42:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalal DH, Patton D, Wojcicki JM, et al. Quality of life in patients postcolectomy for pediatric-onset ulcerative colitis. J Pediatr Gastroenterol Nutr 2012; 55:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozdemir Y, Kiran RP, Erem HH, et al. Functional outcomes and complications after restorative proctocolectomy and ileal pouch anal anastomosis in the pediatric population. J Am Coll Surg 2014; 218:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polites SF, Potter DD, Moir CR, et al. Long-term outcomes of ileal pouch-anal anastomosis for pediatric chronic ulcerative colitis. J Pediatr Surg 2015; 50:1625.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 99093 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25221935" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17681163" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30044358" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19230908" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Impact of Clostridium difficile infection on pediatric inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25268634" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25419679" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Disproportionate rise in Clostridium difficile-associated hospitalizations among US youth with inflammatory bowel disease, 1997-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30540704" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30312400" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29424814" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis-A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21172262" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The role of CMV in steroid-resistant ulcerative colitis: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15104299" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25283582" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33662784" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cytomegalovirus in pediatric inflammatory bowel disease patients with acute severe colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25208108" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25377394" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Opioid analgesia for acute abdominal pain in children: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10950041" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23232326" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20645317" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Acute severe ulcerative colitis in children: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20193683" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26756874" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Corticosteroid Dosing in Pediatric Acute Severe Ulcerative Colitis: A Propensity Score Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31833543" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Antibiotic Cocktail for Pediatric Acute Severe Colitis and the Microbiome: The PRASCO Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30715364" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32087936" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Progression to colectomy in the era of biologics: A single center experience with pediatric ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20104217" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Outcome following infliximab therapy in children with ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20722055" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37477885" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Efficacy and Safety of Tacrolimus or Infliximab Therapy in Children and Young Adults With Acute Severe Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10931411" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Use of infliximab in the treatment of Crohn's disease in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30715240" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29944926" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22155755" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24572593" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Does infliximab prevent colectomy in acute and chronic active ulcerative colitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34153231" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24512909" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11424319" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23063316" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28053054" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11113835" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Oral tacrolimus treatment of severe colitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17873742" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23582736" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Oral tacrolimus for pediatric steroid-resistant ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23615530" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37422724" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Upadacitinib Salvage Therapy for Infliximab experienced patients with Acute Severe Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36122389" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34091545" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24567009" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Off-label use of drugs in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24958064" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25240477" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30935734" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33904583" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Clinical and Host Biological Factors Predict Colectomy Risk in Children Newly Diagnosed With Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19436273" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The natural history of pediatric ulcerative colitis: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30044357" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18085333" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31136563" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : De Novo Crohn's Disease of the Pouch in Children Undergoing Ileal Pouch-Anal Anastomosis for Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36941170" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Surgical Management of Ulcerative Colitis in Children and Adolescents: A Systematic Review from the APSA Outcomes and Evidence-Based Practice Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22395189" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Preoperative immunosuppression is not associated with increased postoperative complications following colectomy in children with colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23002804" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23895969" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Predictive value of the Pediatric Ulcerative Colitis Activity Index in the surgical management of ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29509927" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19403505" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30668719" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Short- and Long-term Outcomes After Ileal Pouch Anal Anastomosis in Pediatric Patients: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17270537" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Surgical complications in relation to functional outcomes after ileoanal anastomosis in pediatric patients with ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22437468" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Quality of life in patients postcolectomy for pediatric-onset ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24468224" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Functional outcomes and complications after restorative proctocolectomy and ileal pouch anal anastomosis in the pediatric population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25863545" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Long-term outcomes of ileal pouch-anal anastomosis for pediatric chronic ulcerative colitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
